ARCA biopharma awards $100K retention bonuses and 40K RSUs each to COO Keuer and CFO Dekker

Oruka Therapeutics, Inc.

COO Thomas Keuer and CFO C. Jeffrey Dekker each receive $100,000 cash retention bonus and 40,000 RSUs.
RSUs vest one year from December 8, 2022, subject to continued employment.
Cash bonus payable upon earlier of a change in control or certain clinical development decisions by the Board.
Unvested RSUs accelerate upon change in control or involuntary termination without cause or for good reason.
Retention incentives designed to retain executives through key corporate milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.